Microglia as a key mediator in rosuvastatin-associated cognitive impairment - PubMed
7 days ago
- #cognitive-impairment
- #rosuvastatin
- #microglia
- Statins, including rosuvastatin, are first-line lipid-lowering therapies but may have cognitive adverse effects.
- The study used network toxicology, in vitro experiments, RNA-sequencing data, computational simulations, and Mendelian randomization analysis.
- Rosuvastatin was found to alter microglial functions such as cell viability, migration, phagocytosis, and inflammatory responses, potentially via the JAK-STAT pathway.
- Disruption of microglial function by rosuvastatin may contribute to cognitive impairment.
- The study provides insights for developing preventive and therapeutic strategies for statin-associated cognitive impairment.